Thesedata suggest that (i) taxanes are a goodcandidate for a second-line therapeutic drug forHNSCC patients with acquired CDDP resistanceand (ii) BRCA1 can be a candidate marker forpredicting an inverse CDDP/taxane sensitivityphenotype in HNSCC. The gene discussed is BRCA1; the disease is head and neck squamous cell carcinoma.